Thalitone Related Published Studies
Well-designed clinical trials related to Thalitone (Chlorthalidone)
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.05]
Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. [2006.03]
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. [2005.04.06]
Well-designed clinical trials possibly related to Thalitone (Chlorthalidone)
Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. [2008.03]
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.01.28]
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2007.11]
Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study. [2007.11]
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. [2007.01]
Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. [2007]
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.11.13]
Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. [2006.10]
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.09]
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. [2006.05.09]
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. [2006.02.07]
Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. [2005.06.28]
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2005.06.27]
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2005.04.25]
Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. [2005.04]
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. [2005.01.01]
Other research related to Thalitone (Chlorthalidone)
Should chlorthalidone be the diuretic of choice for antihypertensive therapy? [2008.08]
Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study. [2008.06]
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.02]
Chlorthalidone inhibits the KvLQT1 potassium current in guinea-pig ventricular myocytes and oocytes from Xenopus laevis. [2008.02]
Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.01.29]
Metabolic and Clinical Outcomes in Non-Diabetic Individuals with the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension: A Report from the ALLHAT Study. [2007.11.13]
Drug-induced acute myopia following chlorthalidone treatment. [2007.09]
Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. [2005.12]
Other possibly related research studies
Survival of severe amlodipine intoxication due to medical intensive care. [2006.09.12]
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2006.05.16]
Thiazide diuretics in the treatment of hypertension: an update. [2006.04]
Role of angiotensin II receptor blockers in atherosclerotic plaque stability. [2006.02]
[Diuretic therapy in heart failure] [2006.01]
Does ALLHAT change the management of hypertension in chronic kidney disease? [2005.12]
An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece. [2005.09]
ALLHAT in perspective: implications to clinical practice and clinical trials. [2005.06]
Systemic hypertension. [2007.04]
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2007.03]
Pharmacoepidemiology of antihypertensive drugs in primary care setting of Bahrain between 1998 and 2000. [2006.10]
Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. [2007.01]
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2007.04]
Sex-Specific Effects of AGT-6 and ACE I/D on Pulse Pressure After 6 Months on Antihypertensive Treatment: The GenHAT Study. [2007.06.30]
[Antihypertensive therapy and renoprotection: do we really need to block the renin-angiotension system?] [2007.09]
Sex-Specific Effects of AGT-6 and ACE I/D on Pulse Pressure After 6 Months on Antihypertensive Treatment: The GenHAT Study. [2007.10]
Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. [2008.04]
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. [2008.01.23]
Improving care in resistant hypertension: medication trends and nonpharmacologic strategies in a specialty clinic. [2007]
Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study. [2008.06]
Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. [2008]
|
